News Daily News $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor Michael O'Riordan May 12, 2017
News Daily News Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value Todd Neale May 04, 2017
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016